Tango Therapeutics Financial Statements
NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tango Therapeutics revenue and earnings
In fiscal 2025, Tango Therapeutics generated $62.4 million in revenue, up 48.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Tango Therapeutics reported a net loss of $101.6 million, compared with a loss of $130.3 million a year earlier. Operating margin was -178.4%.
Diluted earnings per share came in at -$0.87. Over the last 5 fiscal years, TNGX's revenue has grown at a 52.1% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Tango Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 62.38M | 42.07M | 36.53M | 24.86M | 37.04M | 7.66M |
| Revenue growth (YoY) | +48.29% | +15.17% | +46.93% | -32.89% | +383.83% | — |
| Operating Expenses | 173.67M | 187.66M | 150.70M | 135.93M | 95.23M | 59.86M |
| Research & Development | 132.16M | 143.92M | 115.20M | 105.91M | 77.64M | 49.99M |
| Operating Income | -111.29M | -145.59M | -114.17M | -111.07M | -58.19M | -52.20M |
| Other Income (Expense) | 9.70M | 15.50M | 12.56M | 2.95M | 247.00K | 228.00K |
| Pretax Income | -101.59M | -130.09M | -101.61M | -108.12M | -57.94M | -51.97M |
| Income Tax | 4.00K | 208.00K | 134.00K | 54.00K | 292.00K | 0 |
| Net Income | -101.59M | -130.30M | -101.74M | -108.18M | -58.23M | -51.97M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | -1.63 |
| EPS (Diluted) | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | -1.63 |
| Shares Outstanding (Basic) | 116.17M | 109.23M | 94.57M | 87.82M | 62.11M | 31.93M |
| Shares Outstanding (Diluted) | 116.17M | 109.23M | 94.57M | 87.82M | 62.11M | 31.93M |
| EBITDA | -109.01M | -143.10M | -111.76M | -109.46M | -57.29M | -51.48M |
| Operating Margin | -178.39% | -346.09% | -312.57% | -446.79% | -157.09% | -681.82% |
| Net Margin | -162.85% | -309.73% | -278.54% | -435.14% | -157.21% | -678.84% |
This table shows 6 annual periods of Tango Therapeutics's income statement, from FY 2025 back to FY 2020, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow TNGX's reporting calendar. What is a income statement?